Association between codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis

By Chen Jian   Ye Yun   Sun Haozhen   Shi Genming  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 265-272

Springer Publishing Company

Access to resources Recommend Favorite

Des mutations de KRAS aux mutations de RAS : vers une meilleure définition de la réponse aux anticorps anti-EGFR dans le cancer colorectal métastatique

By Lièvre A.  

Oncologie, Vol. 16, Iss. 2-3, 2014-02 ,pp. : 120-128

Springer Publishing Company

Access to resources Recommend Favorite

Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies

By Roovers Rob   Laeremans Toon   Huang Lieven   Taeye Severine   Verkleij Arie   Revets Hilde   Haard Hans   Bergen en Henegouwen Paul M.  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 3, 2007-03 ,pp. : 303-317

Springer Publishing Company

Access to resources Recommend Favorite

Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era

By Van Cutsem Eric  

Targeted Oncology, Vol. 3, Iss. 4, 2008-10 ,pp. : 223-225

Springer Publishing Company

Access to resources Recommend Favorite

Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 11, Iss. 2, 2016-04 ,pp. : 170-183

Bentham Science Publishers

Access to resources Recommend Favorite